Whilst these studies begin to elucidate how CIP2A expression is regulated by EGFR inhibitors and similar therapeutics, further studies are required, and more importantly further studies are necessary to determine whether a reduction in CIP2A expression correlates with the beneficial response of these treatments in LC patients. Here, EGFR is linked to laryngotracheoesophageal cleft.